A basic challenge in the treatment of septic patients in critical care units is the release of bacterial pathogenicity factors such as lipopolysaccharide (LPS, endotoxin) from the cell envelope of Gram-negative bacteria due to killing by antibiotics. LPS aggregates may interact with serum and membrane proteins such as LBP (lipopolysaccharide-binding protein) and CD14 leading to the observed strong reaction of the immune system. Thus, an effective treatment of patients infected by Gram-negative bacteria must comprise beside bacterial killing the neutralization of endotoxins. Here, data are summarized for synthetic compounds indicating the stepwise development to very effective LPS-neutralizing agents. These data include synthetic peptides, based on the endotoxin-binding domains of natural binding proteins such as lactoferrin, Limulus anti-LPS factor, NK-lysin, and cathelicidins or based on LPS sequestering polyamines. Many of these compounds could be shown to act not only in vitro, but also in vivo (e.g . in animal models of sepsis), and might be useful in future clinical trials and in sepsis therapy.
Rietschel ETh , Kirikae T., Schade FU et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J1994; 8: 217—225.
2.
Holzheimer RGThe significance of endotoxin release in experimental and clinical sepsis in surgical patients-evidence for antibiotic-induced endotoxin release?Infection1998; 26: 77—84.
3.
Mock CN, Jurkovich GJ, Dries DJ, Maier RVClinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg1995; 130: 1234—1240.
4.
Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein . Science1990; 249: 1429—1431.
5.
Hailman E., Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med1994; 179: 269—277.
6.
Müller M., Scheel O., Lindner B., Gutsmann T., Seydel U.The role of membrane-bound LBP, endotoxin aggregates, and the MaxiK channel in LPS-induced cell activation. J Endotoxin Res2002; 9: 181—186.
7.
Delude RL, Savedra Jr R., Zhao H. et al. CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA1995; 92: 9288—9292.
8.
Voelker DRLipid transport pathways in mammalian cells. Experientia1990; 46: 569—579.
9.
Henneke P., Golenbock DTInnate immune recognition of lipopolysaccharide by endothelial cells . Crit Care Med2002; 30 (Suppl): S207—S213.
10.
Tobias PS, Soldau K., Ulevitch RJIdentification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem1989; 264: 10867—10871.
11.
Capodici C., Chen S., Sidorczyk Z., Elsbach P., Weiss J.Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal-fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli. Infect Immun1994; 62: 259—265.
12.
Appelmelk BJ , An Y-Q., Thijs BG, MacLaren DM, De Graaff J.Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect Immun1994; 62: 3564—3567.
13.
Hirata M., Shimomoura Y., Yoshida M. et al. Characterization of a rabbit cationic protein (CAP 18) with lipopolysaccharide-inhibitory activity. Infect Immun1994; 62: 1421—1426.
14.
Alpert G., Baldwin G., Thompson C. et al. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis1992; 165: 494—500.
15.
Britigan BE, Serody JS, Cohen MSThe role of lactoferrin as an anti-inflammatory molecule. In: Hutchens TW, Lönnerdal B , and Rumball S. (eds) Lactoferrin: Structure and Function. New York: Plenum, 1994; 143—156.
16.
Machnicki M. , Zimecki M., Zagulski T.Lactoferrin regulates the release of tumor necrosis factor α and interleukin 6 in vivo. Int J Exp Pathol1993; 74: 433—439.
17.
Leippe M.Ancient weapons: NK-lysin is a mammalian homolog to pore-forming peptides of a protozoan parasite. Cell1995; 83: 17—18.
18.
Jerala R., Porro M.Endotoxin neutralizing peptides. Curr Top Med Chem2004; 4: 1173—1184.
19.
Pristrovsek P., Kidric J.Peptides neutralizing lipopolysaccharide — structure and function. Mini Rev Med Chem2001; 1: 409—416.
20.
Blagbrough IS, Geall AJ, David SALipopolyamines incorporating the tetraamine spermine, bound to an alkyl chain, sequester bacterial lipopolysaccharide . Bioorg Med Chem Lett2000; 10: 1959—1962.
21.
Ganz T., Lehrer RIAntimicrobial peptides of vertebrates. Curr Opin Immunol1998; 10: 41—44.
22.
Lehrer RI, Ganz T.Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol1999; 11: 23—27.
23.
Ding L., Yang L., Weiss TM, Waring AJ, Lehrer RI, Huang HWInteraction of antimicrobial peptides with lipopolysaccharides. Biochemistry2003; 42: 12251—12259.
24.
Kastowsky M. , Gutberlet T., Bradaczek H.Comparison of X-ray powder-diffraction data of various bacterial lipopolysaccharide structures with theoretical model conformations. Eur J Biochem1993; 217: 771—779.
25.
Brandenburg K., Koch Mhj, Seydel U.Phase diagram of deep rough mutant lipopolysaccharide from Salmonella minnesota R595. J Struct Biol1992; 108: 93—106.
26.
Seydel U., Koch Mhj, Brandenburg K.Structural polymorphisms of rough mutant lipopolysaccharides Rd to Ra from Salmonella minnesota. J Struct Biol1993; 110: 232—243.
27.
Scott MG, Vreugdenhil Ace, Buurman WA, Hancock Rew, Gold MRCationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol2000; 164: 549—553.
28.
Paus EJ, Willey J., Ridge RJ et al. Production of recombinant endotoxin neutralizing protein in Pichia pastoris and methods for its purification. Protein Expr Purif2002; 26: 202—210.
29.
Fletcher MA , McKenna TM, Quance JL, Wainwright NR, Williams TJLipopolysaccharide detoxification by endotoxin neutralizing protein. J Surg Res1993; 55: 147—154.
30.
Morita T., Ohtsubo S., Nakamura T. et al. Isolation and biological activities of Limulus anticoagulans (anti-LPS factor) which interacts with lipopolysaccharide (LPS). J Biochem1985; 97: 1611—1620.
31.
Hoess A., Watson S., Siber GR, Liddington R.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5Å resolution. EMBO J1993; 12: 3351—3356.
32.
Andrä J., Garidel P., Majerle A. et al. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide. Eur J Biochem2004; 271: 2037—2046.
33.
Ried C., Wahl C., Miethke T. et al. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor . J Biol Chem1996; 271: 28120—28127.
34.
Dankesreiter S., Hoess A., Schneider-Mergener J., Wagner H., Mietke T.Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-α production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol2000; 164: 4804—4811.
35.
Vallespi MG , Alvarez-Obregon JC, Rodriguez-Alonso I. et al. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. Int Immunopharmacol2003; 3: 247—256.
36.
Vallespi MG , Colas M., Garay H., Reyes O., Arana MJDifferential regulation of Th1/Th2 in relevant tissues for sepsis pathogenesis with a Limulus anti-LPS factor-derived peptide increases survival in Gram-positive sepsis. Int Immunopharmacol2004; 4: 1343—1351.
37.
Pristovsek P., Feher K., Szilagyi L., Kidric J.Structure of a synthetic fragment of the LALF protein when bound to lipopolysaccharide. J Med Chem2005; 48: 1666—1670.
38.
Andrä J., Lamata M., Martinez de Tejada G., Bartels R., Koch MH, Brandenburg K.Cyclic antimicrobial peptides based on Limulus anti-lipopolysaccharide factor for neutralization of lipopolysaccharide. Biochem Pharmacol2004; 68: 1297—1307.
39.
Weiss CA, Wasiluk RR, Kellogg TA, Dunn DLBactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor. Surgery2000; 128: 339—344.
40.
Miyata T., Tokunaga F., Yoneya T. et al. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J Biochem1989; 106: 663—668.
41.
Hirakura Y. , Kobayashi S., Matsuzaki K.Specific interactions of the antimicrobial peptide cyclic beta-sheet tachyplesin I with lipopolysaccharides . Biochim Biophys Acta2002; 1562: 32—36.
42.
Zhang L., Scott MG, Yan H., Mayer LD, Hancock Rew.Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry2000; 39: 14504—14514.
43.
Appelmelk BJ , An Y-Q., Geerts M. et al. Lactoferrin is a lipid A-binding protein . Infect Immun1994 ; 62: 2628—2632.
44.
Baveye S., Elass E., Mazurier J., Spik G., Legrand D.Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med1999; 37: 281—286.
45.
Elass-Rochard E., Legrand D., Salmon V. et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein . Infect Immun1998; 66: 486—491.
46.
Elass-Rochard E., Roseanu A., Legrand D. et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28—34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli O55:B5 lipopolysaccharide . Biochem J1995; 312: 839—845.
47.
Chapple DS, Hussain R., Joannou CL et al. Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob Agents Chemother2004; 48: 2190—2198.
48.
Farnaud S., Spiller C., Moriarty LC et al. Interactions of lactoferricin-derived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett2004; 233: 193—199.
49.
Andrä J., Lohner K., Blondelle SE et al. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem J2005; 385: 135—143.
50.
Brandenburg K. , Jürgens G., Müller M., Fukuoka S., Koch Mhj.Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem2001; 382: 1215—1225.
51.
Brandenburg K., Jürgens G., Andrä J. et al. Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endotoxins. Eur J Biochem2002; 269: 5972—5981.
52.
Japelj B., Pristovsek P., Majerle A., Jerala R.Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. J Biol Chem2005 ; 280: 16955—16961.
53.
Zasloff M.Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor . Proc Natl Acad Sci USA1987; 84: 5449—5453.
54.
Rana FR, Sultany CM, Blazyk J.Interactions between Salmonella typhimurium lipopolysaccharide and the antimicrobial peptide, magainin 2 amide. FEBS Lett1990; 261: 464—467.
55.
Rana FR, Blazyk J.Interactions between the antimicrobial peptide, magainin 2, and Salmonella typhimurium lipopolysaccharides. FEBS Lett1991; 293: 11—15.
56.
Matsuzaki K. , Sugishita K., Harada M., Fujii N., Miyajima K.Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta1997; 1327: 119—130.
57.
Cirioni O., Giacometti A., Ghiselli R. et al. Single-dose intraperitoneal magainins improve survival in a Gram-negative-pathogen septic shock rat model. Antimicrob Agents Chemother2002; 46: 101—104.
58.
Ge Y., MacDonald D., Henry MM et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis1999; 35: 45—53.
59.
Giacometti A., Ghiselli R., Cirioni O. et al. Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models . J Antimicrob Chemother2004; 54: 654—660.
60.
Giacometti A., Cirioni O., Ghiselli R. et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides2005; 26: 207—216.
61.
Steiner H., Hultmark D., Engstrom A., Bennich H., Boman HGSequence and specificity of two antibacterial proteins involved in insect immunity. Nature1981; 292: 246—248.
62.
Samakovlis C., Asling B., Boman HG, Gateff E., Hultmark D.In vitro induction of cecropin genes — an immune response in a Drosophila blood cell line . Biochem Biophys Res Commun1992; 188: 1169—1175.
63.
De Lucca AJ , Jacks TJ, Brogden KABinding between lipopolysaccharide and cecropin A. Mol Cell Biochem1995; 151: 141—148.
64.
Bland JM, De Lucca AJ, Jacks TJ, Vigo CBAll-D-cecropin B: synthesis, conformation, lipopolysaccharide binding, and antibacterial activity. Mol Cell Biochem2001 ; 218: 105—111.
65.
Giacometti A., Cirioni O., Ghiselli R. et al. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med2001; 29: 1666—1669.
66.
Ghiselli R. , Giacometti A., Cirioni O. et al. Cecropin B enhances beta-lactam activities in experimental rat models of Gram-negative septic shock. Ann Surg2004; 239: 251—256.
67.
Gough M., Hancock Rew, Kelly NMAntiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun1996; 64: 4922—4927.
68.
Velasco M., Diaz-Guerra MJ, Diaz-Achirica P., Andreu D., Rivas L., Bosca L.Macrophage triggering with cecropin A and melittinderived peptides induces type II nitric oxide synthase expression. J Immunol1997; 158: 4437—4443.
69.
Liepinsh E. , Andersson M., Ruysschaert JM, Otting G.Saposin fold revealed by the NMR structure of NK-lysin. Nat Struct Biol1997; 4: 793—795.
70.
Hecht O., Van Nuland NA, Schleinkofer K. et al. Solution structure of the pore-forming protein of Entamoeba histolytica. J Biol Chem2004; 279: 17834—17841.
71.
Munford RS, Sheppard PO, O'Hara PJSaposin-like proteins (SAPLIP) carry out diverse functions on a common backbone structure. J Lipid Res1995; 36: 1653—1663.
72.
Epaud R., Ikegami M., Whitsett JA, Jobe AH, Weaver TE, Akinbi HTSurfactant protein B inhibits endotoxin-induced lung inflammation . Am J Respir Cell Mol Biol2003; 28: 373—378.
73.
Andersson M. , Girard R., Cazenave P.Interaction of NK-lysin, a peptide produced by cytolytic lymphocytes, with endotoxin. Infect Immun1999; 67: 201—205.
74.
Andrä J., Koch Mhj, Bartels R., Brandenburg K.Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother2004; 48: 1593—1599.
75.
Andersson M. , Gunne H., Agerberth B. et al. NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Vet Immunol Immunopathol1996; 54: 123—126.
76.
Pena SV, Hanson DA, Carr BA, Goralski TJ, Krensky AMProcessing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol1997; 158: 2680—2688.
77.
Endsley JJ, Furrer JL, Endsley MA et al. Characterization of bovine homologues of granulysin and NK-lysin . J Immunol2004; 173: 2607—2614.
78.
Davis EG, Sang Y., Rush B., Zhang G., Blecha F.Molecular cloning and characterization of equine NK-lysin. Vet Immunol Immunopathol2005; 105: 163—169.
Leippe M., Andrä J., Nickel R., Tannich E., Müller-Eberhard HJAmoebapores, a family of membranolytic peptides from cytoplasmic granules of Entamoeba histolytica: isolation, primary structure, and pore formation in bacterial cytoplasmic membranes. Mol Microbiol1994; 14: 895—904.
81.
Stenger S., Hanson DA, Teitelbaum R. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin . Science1998; 282: 121—125.
82.
Ernst WA, Thoma-Uszynski S., Teitelbaum R. et al. Granulysin, a T cell product, kills bacteria by altering membrane permeability. J Immunol2000; 165: 7102—7108.
83.
Andrä J., Herbst R., Leippe M.Amoebapores, archaic effector peptides of protozoan origin, are discharged into phagosomes and kill bacteria by permeabilizing their membranes. Dev Comp Immunol2003; 27: 291—304.
84.
Pena SV, Krensky AMGranulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity. Semin Immunol1997; 9: 117—125.
85.
Berninghausen O., Leippe M.Necrosis versus apoptosis as the mechanism of target cell death induced by Entamoeba histolytica. Infect Immun1997; 65: 3615—3621.
86.
Andrä J., Berninghausen O., Leippe M.Membrane lipid composition protects Entamoeba histolytica from self-destruction by its pore-forming toxins. FEBS Lett2004 ; 564: 109—115. 88. Young JD, Young TM, Lu LP, Unkeless JC, Cohn ZACharacterization of a membrane pore-forming protein from Entamoeba histolytica. J Exp Med1982; 156: 1677—1690.
87.
Gutsmann T., Riekens B., Bruhn H., Wiese A., Seydel U., Leippe M.Interaction of amoebapores and NK-lysin with symmetric phospholipid and asymmetric lipopolysaccharide/phospholipid bilayers. Biochemistry2003; 42: 9804—9812.
88.
Deng A., Chen S., Li Q., Lyu SC, Clayberger C., Krensky AMGranulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol2005; 174: 5243—5248.
89.
Hamamoto K., Shimizu T., Kida Y., Kuwano K.Interactions of a small linear cationic peptide with lipopolysaccharide and lipoteichoic acid. Kurume Med J2003; 50: 99—107.
90.
Andrä J., Leippe M.Candidacidal activity of shortened synthetic analogs of amoebapores and NK-lysin . Med Microbiol Immunol1999; 188: 117—124.
91.
Leippe M., Andrä J., Müller-Eberhard HJCytolytic and antibacterial activity of synthetic peptides derived from amoebapore, the pore-forming peptide of Entamoeba histolytica. Proc Natl Acad Sci USA1994; 91: 2602—2606.
Schromm AB, Brandenburg K., Loppnow H. et al. The charge of endotoxin molecules influences their conformation and interleukin-6 inducing capacity. J Immunol1998; 161: 5464—5471.
94.
Buschner S.Bestimmung der kritischen Aggregatkonzentrationen von Lipiden: Implikationen für die biologische Wirksamkeit von Endotoxinen. PhD thesis, Universität Kiel, 1999.
95.
Zanetti M., Gennaro R., Romeo D.Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett1995; 374: 1—5.
96.
Larrick JW, Morgan JG, Palings I., Hirata M., Yen MHComplementary DNA sequence of rabbit CAP18-a unique lipopolysaccharide binding protein. Biochem Biophys Res Commun1991; 179: 170—175.
97.
Cowland JB, Johnsen AH, Borregaard N.hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett1995; 368: 173—176.
98.
Malm J., Sorensen O., Persson T. et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun2000; 68: 4297—4302.
99.
Frohm M., Gunne H., Bergman AC et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem1996; 237: 86—92.
100.
Agerberth B., Grunewald J., Castanos-Velez E. et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med1999; 160: 283—290.
101.
Hirata M., Zhong J., Wright SC, Larrick JWStructure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res1995; 392: 317—326.
102.
Travis SM, Anderson NN, Forsyth WR et al. Bactericidal activity of mammalian cathelicidin-derived peptides . Infect Immun2000; 68: 2748—2755.
103.
Turner J., Cho Y., Dinh N-N., Waring AJ, Lehrer RIActivities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother1998 ; 42: 2206—2214.
104.
Oren Z., Lerman JC, Gudmundsson GH, Agerberth B., Shai Y.Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity . Biochem J1999; 341: 501—513.
105.
Pathak N., Salas-Auvert R., Ruche G., Janna M-H., McCarthy D., Harrison RGComparison of the effects of hydrophobicity, amphiphilicity, and α-helicity on the activities of antimicrobial peptides. Proteins1995; 22: 182—186.
106.
Chen C., Brock R., Luh F. et al. The solution structure of the active domain of CAP18-a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett1995; 370: 46—52.
107.
Tossi A., Scocchi M., Skerlavaj B., Gennaro R.Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett1994; 339: 108—112.
108.
de Haas CJ , Haas PJ, van Kessel KP, van Strijp JAAffinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem Biophys Res Commun1998 ; 252: 492—496.
109.
Larrick JW , Hirata M., Shimomoura Y. et al. Antimicrobial activity of rabbit CAP18-derived peptides. Antimicrob Agents Chemother1993 ; 37: 2534—2539.
110.
Turner J., Cho Y., Dinh N-N., Waring AJ, Lehrer RIActivities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother1998 ; 42: 2206—2214.
111.
Hirata M., Shimomura Y., Yoshida M., Wright SC, Larrick JWEndotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Prog Clin Biol Res1994; 388: 147—159.
112.
Sawa T., Kurahashi K., Ohara M. et al. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother1998 ; 42: 3269—3275.
113.
Kirikae T. , Hirata M., Yamasu H. et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP 18)-derived peptide against murine endotoxemia . Infect Immun1998; 66: 1861—1868.
114.
Nagaoka I. , Hirota S., Niyonsaba F. et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol2001; 167: 3329—3338.
115.
Nagaoka I. , Hirota S., Niyonsaba F. et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol2002 ; 9: 972—982.
116.
Nell MJ, Tjabringa GS, Wafelman AR et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application . Peptides2006; 27: 649—660.
117.
Ciornei CD , Sigurdardottir T., Schmidtchen A., Bodelsson M.Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother2005; 49: 2845—2850.
118.
Zhu Y., Ho B., Ding JLSequence and structural diversity in endotoxin-binding dodecapeptides. Biochim Biophys Acta2003; 1611: 234—242.
119.
Bosshart H. , Heinzelmann M.Endotoxin-neutralizing effects of histidine-rich peptides. FEBS Lett2003 ; 553: 135—140.
Wasiluk KR , Leslie DB, Vietzen PS, Mayo KH, Dunn DLStructure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery2004; 136: 253—260.
122.
Papo N., Shai Y.A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem2005 ; 280: 10378—10387.
123.
Rosenfeld Y., Papo N., Shai Y.Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem2006; 281: 1636—1743.
124.
Jiao BH, Freudenberg M., Galanos C.Characterization of the lipid A component of genuine smooth-form lipopolysaccharide . Eur J Biochem1989; 180: 515—518.
125.
Huber M., Kalis C., Keck S. et al. R-form LPS, the master key to the activation of TLR4/MD-2-positive cells. Eur J Immunol2006; 36: 701—711.
126.
David SA, Bechtel B., Annaiah C., Mathan VI, Balaram P.Interaction of cationic amphiphilic drugs with lipid A: Implications for development of endotoxin antagonists. Biochim Biophys Acta1994; 1212: 167—175.
127.
David SA, Awasthi SK, Balaram P.The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. J Endotoxin Res2000; 6: 249—256.
128.
David SATowards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J Mol Recognit2001; 14: 370—387.
129.
Burns MR, Wood SJ, Miller KA, Nguyen T., Cromer JR, David SALysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg Med Chem2005; 13: 2523—2536.
130.
David SA, Silverstein R., Amura CR, Kielian T., Morrison DCLipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother1999; 43: 912—919.
131.
Cromer JR, Wood SJ, Miller KA, Nguyen T., David SAFunctionalized dendrimers as endotoxin sponges. Bioorg Med Chem Lett2005; 15: 1295—1298.
132.
Behr JP, Demeneix B., Loeffler JP, Perez-Mutul J.Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA1989; 86: 6982—6986.
133.
Kiefer K., Clement J., Garidel P., Peschka-Suss R.Transfection efficiency and cytotoxicity of nonviral gene transfer reagents in human smooth muscle and endothelial cells. Pharm Res2004; 21: 1009—1017.
134.
Wood SJ, Miller KA, David SAAnti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide-recognizing motifs in small molecules. Comb Chem High Throughput Screen2004; 7: 733—747.
135.
Tomalia DA , Naylor AM, Goddard III WA. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Edn Engl2005; 29: 138—175.
136.
David S., Perez L., Infante MRSequestration of bacterial lipopolysaccharide by bis(Args) gemini compounds . Bioorg Med Chem Lett2002; 12: 357—360.
137.
Zorko M., Majerle A., Sarlah D., Keber MM, Mohar B., Jerala R.Combination of antimicrobial and endotoxin-neutralizing activities of novel oleoylamines. Antimicrob Agents Chemother2005; 49: 2307—2313.
138.
Duwe AK, Rupar CA, Horsman GB, Vos SIIn vitro cytotoxicity and antibiotic activity of polymyxin B nonapeptide. Antimicrob Agents Chemother1986; 30: 340—341.
139.
Schromm AB , Brandenburg K., Rietschel ETh, Flad H-D, Carroll SF, Seydel U. Lipopolysaccharide binding protein (LBP) mediates CD 14-independent intercalation of lipopolysaccharide into phospholipid membranes. FEBS Lett1996; 399: 267—271.
140.
Takayama K. , Mitchell DH, Din ZZ, Mukerjee P., Li C., Coleman DLMonomeric Re lipopolysaccharide from Escherichia coli is more active than the aggregated form in the Limulus amebocyte assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem1994; 269: 2241—2244.
141.
Shnyra A., Hultenby K., Lindberg AARole of the physical state of Salmonella lipopolysaccharide in expression of biological and endotoxic properties. Infect Immun1993; 61: 5351—5360.
142.
Mueller M. , Lindner B., Kusumoto S., Fukase K., Schromm AB, Seydel U.Aggregates are the biologically active units of endotoxin. J Biol Chem2004; 279: 26307—26313.
143.
Mueller M. , Lindner B., Dedrick R., Schromm AB, Seydel U.Endotoxin: physical requirements for cell activation. J Endotoxin Res2005; 11: 299—303.
144.
Gutsmann T. , Müller M., Carroll SF, McKenzie RC, Wiese A., Seydel U.Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun2001; 69: 6942—6950.
145.
Blunck R., Scheel O., Müller M., Brandenburg K., Seitzer U., Seydel U.New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling. J Immunol2001; 166: 1009—1015.
146.
Gioannini TL, Zhang D., Teghanemt A., Weiss JPAn essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem2002; 277: 47818—47825.
147.
Grubert A. , Mancek M., Wagner H., Kirschning CJ, Jerala R.Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition . J Biol Chem2004; 279: 28475—28482.
148.
Teghanemt A., Zhang D., Levis EN, Weiss JP, Gioannini TLMolecular basis of reduced potency of underacylated endotoxins. J Immunol2005; 175: 4669—4676.
